1. Gojanovich AD, Le NTT, Mercer RCC, Park S, Wu B, Anane A, Vultaggio JS, Mostoslavsky G, Harris DA. Abnormal synaptic architecture in iPSC-derived neurons from a multi-generational family with genetic Creutzfeldt-Jakob disease. Stem Cell Reports. 2024 Oct 08; 19(10):1474-1488.View Related Profiles.

   Gojanovich, Aldana
   Harris, David
   Mostoslavsky, Gustavo
   Mercer, Robert
   

   PMID: 39332406
2. Mercer RCC, Le NTT, Fraser DG, Houser MCQ, Beeler AB, Harris DA. Sigma Receptor Ligands Are Potent Antiprion Compounds that Act Independently of Sigma Receptor Binding. ACS Chem Neurosci. 2024 Jun 05; 15(11):2265-2282.View Related Profiles.

   Harris, David
   Mercer, Robert
   

   PMID: 38743607
3. Mercer RCC, Le NTT, Houser MCQ, Beeler AB, Harris DA. Sigma receptor ligands are potent anti-prion compounds that act independently of sigma receptor binding. bioRxiv. 2023 Nov 29.View Related Profiles.

   Harris, David
   Mercer, Robert
   

   PMID: 38077011; PMCID: PMC10705434; DOI: 10.1101/2023.11.28.569035;
4. Mercer RCC, Harris DA. Mechanisms of prion-induced toxicity. Cell Tissue Res. 2023 Apr; 392(1):81-96.View Related Profiles.

   Harris, David
   Mercer, Robert
   

   PMID: 36070155
5. Mercer RC, Harris DA. Identification of anti-prion drugs and targets using toxicity-based assays. Curr Opin Pharmacol. 2019 02; 44:20-27.View Related Profiles.

   Harris, David
   Mercer, Robert
   

   PMID: 30684854; PMCID: PMC6561806; DOI: 10.1016/j.coph.2018.12.005;
6. Fang C, Wu B, Le NTT, Imberdis T, Mercer RCC, Harris DA. Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathog. 2018 09; 14(9):e1007283.View Related Profiles.

   Wu, Bei
   Harris, David
   Le, Nhat
   Mercer, Robert
   

   PMID: 30235355; PMCID: PMC6147624; DOI: 10.1371/journal.ppat.1007283;
7. Mercer RCC, Daude N, Dorosh L, Fu ZL, Mays CE, Gapeshina H, Wohlgemuth SL, Acevedo-Morantes CY, Yang J, Cashman NR, Coulthart MB, Pearson DM, Joseph JT, Wille H, Safar JG, Jansen GH, Stepanova M, Sykes BD, Westaway D. A novel Gerstmann-Sträussler-Scheinker disease mutation defines a precursor for amyloidogenic 8 kDa PrP fragments and reveals N-terminal structural changes shared by other GSS alleles. PLoS Pathog. 2018 01; 14(1):e1006826. PMID: 29338055; PMCID: PMC5786331; DOI: 10.1371/journal.ppat.1006826;
8. Lau A, McDonald A, Daude N, Mays CE, Walter ED, Aglietti R, Mercer RC, Wohlgemuth S, van der Merwe J, Yang J, Gapeshina H, Kim C, Grams J, Shi B, Wille H, Balachandran A, Schmitt-Ulms G, Safar JG, Millhauser GL, Westaway D. Octarepeat region flexibility impacts prion function, endoproteolysis and disease manifestation. EMBO Mol Med. 2015 Mar; 7(3):339-56. PMID: 25661904; PMCID: PMC4364950; DOI: 10.15252/emmm.201404588;
9. Mays CE, Coomaraswamy J, Watts JC, Yang J, Ko KW, Strome B, Mercer RC, Wohlgemuth SL, Schmitt-Ulms G, Westaway D. Endoproteolytic processing of the mammalian prion glycoprotein family. FEBS J. 2014 Feb; 281(3):862-76. PMID: 24286250
10. Mercer RC, Ma L, Watts JC, Strome R, Wohlgemuth S, Yang J, Cashman NR, Coulthart MB, Schmitt-Ulms G, Jhamandas JH, Westaway D. The prion protein modulates A-type K+ currents mediated by Kv4.2 complexes through dipeptidyl aminopeptidase-like protein 6. J Biol Chem. 2013 Dec 27; 288(52):37241-55. PMID: 24225951; PMCID: PMC3873577; DOI: 10.1074/jbc.M113.488650;

Repurposing human-approved drugs for prion disease treatment